Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Nicola Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne, Andrea Huppertz, Alexandra Carls, Walter-Emil Haefeli, Ekkehard Grünig. Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension. Eur Respir J 2016; 48: Suppl. 60, 2396

Member's Comments

No comment yet.

Related content which might interest you: Switching to macitentan in pulmonary arterial hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Liver toxicity of sitaxentan in pulmonary arterial hypertension Source: Eur Respir J 2011; 37: 475 Year: 2011 Population pharmacokinetics of imatinib in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1 Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Assessment of simvastatin treatment on pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013